Ado-Trastuzumab Emtansine: all 87 studies that test it
Page 1 of 1. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.
- Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingNCT07825753Phase 2
- A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast CancerRecruitingNCT07673029Phase 3
- The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerRecruitingNCT06439693Phase 2
- Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast CancerRecruitingNCT06299852Not applicable
- Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP TherapyRecruitingNCT06125834Phase 2
- A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)RecruitingNCT05673928Phase 2
- Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland CancersRecruitingNCT05408845Phase 2
- Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast CancerRecruitingNCT05288777Phase 2/3
- ATEMPT 2.0: Adjuvant T-DM1 vs THRecruitingNCT04893109Phase 2
- Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular DysfunctionRecruitingNCT04680442Phase 2
- Post-op T-DM1 in HER-2+ Salivary Gland CarcinomasRecruitingNCT04620187Phase 2
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingNCT04486352Phase 1/2
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingNCT04341181Phase 2
- Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)Not yet recruitingNCT04301375Phase 2
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
- A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of ResponseCompletedNCT04632992Phase 2Results posted
- Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)Active, not recruitingNCT04439110Phase 2Results posted
- ATOP TRIAL: T-DM1 in HER2 Positive Breast CancerActive, not recruitingNCT03587740Phase 2Results posted
- 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast CancerCompletedNCT03364348Phase 1Results posted
- A Study Of Pembrolizumab In Combination With Trastuzumab-DM1CompletedNCT03032107Phase 1Results posted
- A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid TumorsCompletedNCT02999672Phase 2Results posted
- A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a TaxaneCompletedNCT02658734Phase 4Results posted
- Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast CancerTerminatedNCT02658084Phase 1/2Results posted
- An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.CompletedNCT02657343Phase 1/2Results posted
- T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCAActive, not recruitingNCT02326974Phase 2Results posted
- A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02289833Phase 2Results posted
- A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast CancerCompletedNCT02236000Phase 1/2Results posted
- Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast CancerActive, not recruitingNCT02226276Not applicableResults posted
- A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast CancerTerminatedNCT02144012Phase 3Results posted
- A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerCompletedNCT02131064Phase 3Results posted
- Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With PaclitaxelCompletedNCT02073487Phase 2Results posted
- BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane TxCompletedNCT02038010Phase 1Results posted
- A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast CancerCompletedNCT01966471Phase 3Results posted
- Cardiac Safety Study in Patients With HER2 + Breast CancerCompletedNCT01904903Phase 2Results posted
- T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)CompletedNCT01853748Phase 2Results posted
- A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)CompletedNCT01772472Phase 3Results posted
- A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based TreatmentCompletedNCT01702571Phase 3Results posted
- A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric CancerTerminatedNCT01641939Phase 2/3Results posted
- HKI-272 for HER2-Positive Breast Cancer and Brain MetastasesCompletedNCT01494662Phase 2Results posted
- A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed TherapyCompletedNCT01419197Phase 3Results posted
- A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast CancerCompletedNCT01196052Phase 2Results posted
- A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)CompletedNCT01120184Phase 3Results posted
- Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease ProgressionCompletedNCT00943670Phase 2Results posted
- A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing RegimenCompletedNCT00932373Phase 1Results posted
- A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received TrastuzumabCompletedNCT00875979Phase 1/2Results posted
- A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast CancerCompletedNCT00829166Phase 3Results posted
- A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic DiseaseCompletedNCT00679341Phase 2Results posted
- A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast CancerCompletedNCT00679211Phase 2Results posted
- A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerCompletedNCT00509769Phase 2Results posted
- HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast CancerTerminatedNCT06595563Phase 2
- A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerActive, not recruitingNCT06316531Phase 3
- A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast CancerActive, not recruitingNCT06265428Phase 3
- Precise Therapy for Refractory HER2 Positive Advanced Breast CancerStatus unknownNCT05429684Phase 3
- Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of TucatinibActive, not recruitingNCT05323955Phase 2
- SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingNCT04931342Phase 2
- Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast CancerActive, not recruitingNCT04733118Phase 2
- De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 BlockadeTerminatedNCT04675827Phase 2
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingNCT04591431Phase 2
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingNCT04589845Phase 2
- Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast CancerWithdrawnNCT04419181Phase 2
- Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerTerminatedNCT04042051Phase 1
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLCTerminatedNCT03784599Phase 2
- A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast CancerTerminatedNCT03429101Phase 1
- Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib.Status unknownNCT03418558Phase 2
- Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal CancerStatus unknownNCT03225937Phase 2
- Kadcyla In pAtients With bRAin MetastasisWithdrawnNCT03203616Phase 2
- Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast CancerCompletedNCT03153163Phase 1
- Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast CancerCompletedNCT03084939Phase 3
- Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast CancerWithdrawnNCT02725541Phase 2
- Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant CancersCompletedNCT02675829Phase 2
- Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast CancerCompletedNCT02605915Phase 1
- Neoadjuvant Response-guided Treatment of HER2 Positive Breast CancerActive, not recruitingNCT02568839Phase 2/3
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
- Deciphering Antitumour Response and Resistance With INtratumour HeterogeneityCompletedNCT02314481Phase 2
- Patients With Brain Metastases From HER2-positive Breast CancerCompletedNCT02135159Phase 1
- T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast CancerCompletedNCT02073916Phase 1
- A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast CancerCompletedNCT01983501Phase 1
- Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)CompletedNCT01976169Phase 1
- Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.CompletedNCT01975142Phase 2
- Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by SurgeryCompletedNCT01816035Phase 1
- A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.CompletedNCT01745965Phase 2
- HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1CompletedNCT01565200Phase 2
- A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic FunctionCompletedNCT01513083Phase 1
- Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based TherapyCompletedNCT00928330Phase 1
- A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent StudiesActive, not recruitingNCT00781612Phase 2